Labiotech.eu’s Post

Biotech Funding Update July 15th-19th ‘24 Significant funding events, many to advance clinical stage assets.. Get this weekly • https://lnkd.in/gDGtEEyy – 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Cardurion Pharmaceuticals 💸  Raised $260M in Series B financing led by Ascenta Capital to support late-stage trials of lead drug candidates. Scorpion Therapeutics 💸  Announced $150M Series C financing co-led by Frazier Life Sciences and Lightspeed Venture Partners to advance precision oncology assets. CatalYm GmbH 💸  Announced $150M Series D financing to support Ph 2b development of Visugromab Magenta Medical Ltd. 💸  Closed $105M financing led by several healthcare investors to advance the company's U.S. clinical programs in multiple MCS indications and to secure the first FDA approval for the Elevate™ System in patients undergoing HR-PCI. Asceneuron SA 💸 Secured $100M in Series C financing led by Novo Holdings to advance Ph2 development of ASN51 for treating Alzheimer's disease. – 𝐏𝐨𝐬𝐭-𝐈𝐏𝐎/𝐏𝐮𝐛𝐥𝐢𝐜 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Artiva Biotherapeutics 🏦  Raised $167M in an IPO at $12/share. NGM Biopharmaceuticals 🏦  Announced $122M Series A led by TCG funding to initiate PSC trial and fund Ph2 trial in hyperemesis gravidarum. OPKO Health, Inc. 🏦  Announced a $100M share repurchase program. LENZ Therapeutics 🏦  Entered a $30M stock purchase agreement with Ridgeback Capital Investments. MediWound 🏦  Announced a $25M private placement offering. At BiopharmIQ by Amp we maintain biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma

Global pharma company backs cancer drug developer A UK drug development company co-founded by Australian Tom McCarthy (picture) has attracted strategic investment from a global pharmaceuticals business in a $38 million capital raising round. The company, which is also backed by Australian venture capital, plans clinical trials for its lead cancer drug candidate in Australia late this year. Read more about this, and much more about venture capital and private equity, at: https://lnkd.in/gE-aPUTb #venturecapital #privateequity

Some noticeable licensing and fundraising deals yesterday in the Biotech Space: Vertex Pharmaceuticals agree to license Orum Therapeutics degrader-antibody conjugate technology for $15 million upfront plus $310 million per target in milestones plus royalties on future sales - Greg Dwyer Cardurion Pharmaceuticals announce a $260M Series B who have now raised over $500M – funds will be used to advance it’s pipeline for Cardiovascular diseases. Neuspera Medical Inc. secured a $23M Series D led by Vertex Ventures HC and Treo Ventures, with participation from Action Potential Venture Capital, Windham Venture Partners & Olympus Innovation Ventures. SOTIO Biotech & Biocytogen announced a research collaboration, exclusive option and license agreement. Under the agreement, Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million. Full-Life Technologies agree a $571.5M deal with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound.   Asceneuron SA secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Disease.

#fundingalert 💼Company: Pathios Therapeutics 💰Funding: €23.4 Million ⚡Round: Series B  👥Investors: Bristol Myers Squibb, Canaan and Brandon Capital. Launched in 2017, Pathios is a drug discovery and development company focused on translating innovative science into new medicines. Pathios was founded by a team of experienced biotech and pharmaceutical industry professionals, entrepreneurs, and clinicians. Proceeds from the raise will be used to support the continued development of Pathios’ unique approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases. Tom McCarthy, Stuart Hughes, Shelley Cook, David Miller, Barbara Cipriani, Anthony J. Good, PhD Read more - https://lnkd.in/gGQbUjbg To share your startup story write us on - contact@startuprise.co.uk #Pathios #development #innovative #medtech #immunotherapy #biotech #pharmaceutical #funding #fundingnews #startupnews #news #startuprise

Only a few days remain until the highlight of the year for the exosome commercial space—the upcoming Exosome Based Therapeutics Summit in Boston (https://lnkd.in/de6XTYeP). If you are attending or will be in the area and have an interest in the rapidly advancing fields of exosome therapies, exosome-based diagnostics, or exosome-based drug delivery platforms, we invite you to connect with us. Whether you are an investor exploring groundbreaking innovations, a start-up or pharmaceutical company seeking partnerships to develop cutting-edge exosome-based therapies, or part of the academic community aiming to translate exosome-based discoveries into commercial ventures, we are here to support you. Our Managing Director, Konstantin Glebov, will be present at the summit. Connect with him to learn how our data-first approach helps accelerate your exosome-focused projects. Our unique KnowlExCloud business intelligence platform provides comprehensive insights into the exosome landscape to meet your development needs, identify strategic opportunities, and mitigate risks—ultimately increasing the probability of success in your exosome projects. #ExosomeSummit #Boston #ExosomeConsulting #VesicleTherapeutics #Networking #Investors #StartUps #Pharma #ExosomeTherapies #DrugDelivery #Diagnostics #Exosomes #ExtracellularVesicles

Apart from the #Novo_deal, #Gilead_Sciences acquired #CymaBay_Therapeutics for $4.3 billion. #Ambrx_Biopharma, an ADC company, was acquired by #J&J for $2 billion, and #AstraZeneca made an announcement about acquiring #Fusion_Pharmaceuticals, which happens to be US-based, for $2 billion. All these highlight the strategic pursuit of therapies that happen to be driving the sector forward. It is well to be noted that #oncology #emerges as the #top_therapy_area when it comes to #M&A deals in Q1 of 2024, with a phenomenal deal value of $29 billion, says GlobalData. #Immunology_centric M&As went on to #experience the #highest_growth when it came to deal activity vis-à-vis Q1 of 2023, thereby seeing a whopping 314% rise in the deal value, which totaled $14 billion.

#Phispers Week 6 - Weekly Pharma News Recap Bonjour, - Novo Nordisk’s parent buys Catalent Pharma Solutions for US$ 16.5 bn, Eli Lilly and Company calls for scrutiny - Novartis buys MorphoSys for US$ 2.9 bn, gains promising bone-marrow cancer med - Amgen’s weight-loss drug shows impressive results in early-stage trial - Johnson & Johnson Innovative Medicine’s closely watched autoimmune drug succeeds in mid, late-stage trials #Phispers this week - PharmaCompass.com's Weekly News Recap #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmacompass https://lnkd.in/ddDksT4p

$175M in new funding is no small thing for a biotech startup... Aktis Oncology’s $175M Series B round, led by RA Capital Management with participation from RTW Investments, LP, Janus Henderson Group PLC, and strategic investors like Eli Lilly and Company and Bristol Myers Squibb, is a significant development in the radiopharmaceutical space. This funding positions Aktis to advance its lead candidate, AKY-1189, targeting Nectin-4 in solid tumors. The involvement of industry leaders and prominent investors reflects the growing confidence in targeted radiopharmaceuticals as a next-generation cancer treatment, signaling a larger shift in oncology toward precision therapies that aim to improve efficacy and minimize side effects. Matthew Roden Dave Ricks Giovanni Caforio Merck MRL Ventures Fund LLC Rob Davis Peter Kolchinsky Roderick Wong Ali Dibadj T. Rowe Price Rob Sharps Avidity Partners #Biotech #Radiopharmaceuticals #OncologyInnovation #PrecisionMedicine #CancerResearch #Innovation #VentureCapitalists #VCFunding #ClinicalTrials https://lnkd.in/ej9fvC-U https://lnkd.in/evi2Qntw https://lnkd.in/eHCjFbyS

Weekly Recap of the Hottest M&A and Partnerships in the Biotech World! 🔥🤝 Merger and acquisition: 🔀 🇺🇸 Gilead Sciences acquires 🇺🇸 CymaBay Therapeutics | $4.3 billion equity value | PPAR delta agonist for primary biliary cholangitis 🇦🇺 Telix Pharmaceuticals Limited to acquire 🇺🇸 QSAM Biosciences, Inc. | QSAM to receive $33.1 million in ordinary shares and up to $90 million in future milestone payments | clinical radiopharmaceutical candidate for bone cancer Partnering: 🤝 🇺🇸 VantAI collaborates with 🇺🇸 Bristol Myers Squibb to accelerate AI-based molecular glue drug discovery | VantAI is eligible to receive up to $674 million in milestone payments 🇺🇸 Shattuck Labs partners with 🇯🇵 ONO PHARMACEUTICAL CO., LTD. to develop bifunctional fusion proteins for autoimmune and inflammatory diseases | Shattuck to receive up to $227 million in milestone payments 🇩🇪 BioNTech SE and 🇬🇧 Autolus Therapeutics collaborate to advance CAR-T cell therapy pipeline | BioNTech to invest $200 million in Autolus 🇺🇸 BridgeBio and 🇯🇵 Kyowa Kirin Co., Ltd. collaborate to develop and commercialize skeletal dysplasia candidate in Japan | BridgeBio to receive $100 million upfront Subscribe to our newsletter for more partnering updates!  🔗 https://lnkd.in/dsgz62YY #deals #partnering #mergers #acquisitions #biotech

With a looming patent cliff, 2023 saw pharma dealmakers actively deploying their reserves of dry powder to replenish their therapeutic pipelines across a number of key indications. Further deals were announced in January in the run up to JPM Healthcare. This week, Novartis announced it was to buy German biotech MorphoSys for $2.9bn, capping 20 years of therapeutic antibody collaboration and hands Novartis a key oncology asset on the verge of regulatory filings. In 2007, the two parties formed a 10-year, $600 million deal to create therapeutic antibodies. Their collaboration yielded ianalumab in multiple Phase III studies in various autoimmune diseases and has blockbuster potential. Table: Biopharma's $2bn acquisitions in 2023. Source - Endpoints News #novartis #morphosys #pharmaindustry #biopharma #pharmacompanies